3.46
price up icon2.98%   0.10
after-market Dopo l'orario di chiusura: 3.48 0.02 +0.58%
loading
Precedente Chiudi:
$3.36
Aprire:
$3.335
Volume 24 ore:
568.28K
Relative Volume:
0.24
Capitalizzazione di mercato:
$289.65M
Reddito:
$32.31M
Utile/perdita netta:
$-237.09M
Rapporto P/E:
-1.2014
EPS:
-2.88
Flusso di cassa netto:
$-219.11M
1 W Prestazione:
+21.83%
1M Prestazione:
+64.76%
6M Prestazione:
+145.39%
1 anno Prestazione:
-38.32%
Intervallo 1D:
Value
$3.3347
$3.485
Intervallo di 1 settimana:
Value
$2.66
$3.485
Portata 52W:
Value
$0.9101
$5.85

Editas Medicine Inc Stock (EDIT) Company Profile

Name
Nome
Editas Medicine Inc
Name
Telefono
617-401-9000
Name
Indirizzo
11 HURLEY ST., CAMBRIDGE, MA
Name
Dipendente
226
Name
Cinguettio
@editasmed
Name
Prossima data di guadagno
2025-05-02
Name
Ultimi documenti SEC
Name
EDIT's Discussions on Twitter

Confronta EDIT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
EDIT
Editas Medicine Inc
3.46 281.28M 32.31M -237.09M -219.11M -2.88
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-28 Iniziato H.C. Wainwright Buy
2024-12-16 Downgrade JP Morgan Neutral → Underweight
2024-12-13 Downgrade Chardan Capital Markets Buy → Neutral
2024-12-13 Downgrade Stifel Buy → Hold
2024-12-13 Downgrade Truist Buy → Hold
2024-12-11 Downgrade Wells Fargo Overweight → Equal Weight
2024-11-25 Downgrade BofA Securities Buy → Underperform
2024-11-06 Aggiornamento Evercore ISI In-line → Outperform
2024-11-04 Downgrade Raymond James Outperform → Mkt Perform
2024-08-08 Aggiornamento BofA Securities Neutral → Buy
2024-05-09 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2023-10-24 Aggiornamento Citigroup Neutral → Buy
2023-10-18 Aggiornamento JP Morgan Underweight → Neutral
2023-10-17 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-09-29 Aggiornamento Stifel Hold → Buy
2023-06-12 Aggiornamento Raymond James Mkt Perform → Outperform
2023-02-01 Iniziato Cantor Fitzgerald Overweight
2022-12-13 Iniziato Citigroup Neutral
2022-12-06 Ripresa Credit Suisse Neutral
2022-11-18 Downgrade Credit Suisse Outperform → Neutral
2022-11-18 Downgrade Oppenheimer Outperform → Perform
2022-09-29 Iniziato BofA Securities Neutral
2021-10-19 Iniziato SVB Leerink Mkt Perform
2021-09-24 Iniziato Stifel Hold
2021-09-10 Aggiornamento Oppenheimer Perform → Outperform
2021-08-09 Aggiornamento Truist Hold → Buy
2021-08-05 Aggiornamento Evercore ISI Underperform → Outperform
2021-06-04 Ripresa Robert W. Baird Outperform
2021-05-04 Iniziato RBC Capital Mkts Sector Perform
2021-04-16 Iniziato Goldman Sell
2021-03-22 Iniziato Credit Suisse Outperform
2021-03-01 Downgrade Barclays Overweight → Equal Weight
2021-02-26 Downgrade Truist Buy → Hold
2021-01-19 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-01-07 Downgrade Raymond James Outperform → Mkt Perform
2020-12-10 Aggiornamento Wells Fargo Equal Weight → Overweight
2020-11-03 Iniziato Robert W. Baird Underperform
2020-06-18 Ripresa SunTrust Buy
2020-02-21 Iniziato Wells Fargo Equal Weight
2019-04-12 Iniziato Evercore ISI Outperform
2018-10-10 Iniziato Guggenheim Neutral
2018-09-21 Iniziato Raymond James Outperform
2018-05-15 Reiterato Chardan Capital Markets Buy
2018-02-13 Iniziato CLSA Underperform
2018-01-23 Aggiornamento SunTrust Hold → Buy
2017-07-14 Iniziato SunTrust Hold
2017-03-28 Iniziato Chardan Capital Markets Buy
2016-08-10 Aggiornamento Jefferies Hold → Buy
2016-06-02 Iniziato Jefferies Hold
2016-02-29 Iniziato JMP Securities Mkt Outperform
2016-02-29 Iniziato JP Morgan Neutral
2016-02-29 Iniziato Morgan Stanley Equal-Weight
Mostra tutto

Editas Medicine Inc Borsa (EDIT) Ultime notizie

pulisher
12:47 PM

What analysts say about Editas Medicine Inc. stockBreakout stock performance - Autocar Professional

12:47 PM
pulisher
Jul 22, 2025

Is Editas Medicine Inc. a good long term investmentExceptional profit margins - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

Editas Medicine Inc. Stock Analysis and ForecastUnrivaled growth potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

There's Reason For Concern Over Editas Medicine, Inc.'s (NASDAQ:EDIT) Massive 42% Price Jump - simplywall.st

Jul 22, 2025
pulisher
Jul 20, 2025

What drives Editas Medicine Inc. stock priceConsistent high-yield stocks - Autocar Professional

Jul 20, 2025
pulisher
Jul 19, 2025

What makes Editas Medicine Inc. stock price move sharplyVerified Return Tips - beatles.ru

Jul 19, 2025
pulisher
Jul 15, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Hold" from Brokerages - MarketBeat

Jul 15, 2025
pulisher
Jul 14, 2025

Numerous Editas Medicine Insiders Sold Stock: Not A Positive Omen - simplywall.st

Jul 14, 2025
pulisher
Jul 10, 2025

Crispr Genomic Cure Market in 2032: A Glimpse Into the Future - openPR.com

Jul 10, 2025
pulisher
Jul 09, 2025

Editas Medicine (EDIT) Soars 7.69% on Positive Data - AInvest

Jul 09, 2025
pulisher
Jul 08, 2025

Cathie Wood shells out $13.9 million for one high-stakes biotech stock - Yahoo Finance

Jul 08, 2025
pulisher
Jul 08, 2025

Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data - MSN

Jul 08, 2025
pulisher
Jul 02, 2025

Restore Health – Therapies that cureTelethon - Ricerca Malattie Genetiche Rare

Jul 02, 2025
pulisher
Jun 30, 2025

Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 3000E Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Top 10 CRISPR Stocks to Buy Now - Insider Monkey

Jun 30, 2025
pulisher
Jun 28, 2025

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? - The Motley Fool

Jun 28, 2025
pulisher
Jun 27, 2025

2 Beaten-Down Stocks to Avoid - The Globe and Mail

Jun 27, 2025
pulisher
Jun 25, 2025

Gene Editing Market Set to Witness Significant Growth by 2025-2032 | CRISPR Therapeutics, Editas Medicine - openPR.com

Jun 25, 2025
pulisher
Jun 20, 2025

Gene editing stocks gain amid FDA's latest leadership change (EDIT:NASDAQ) - Seeking Alpha

Jun 20, 2025
pulisher
Jun 19, 2025

Cancer Gene Therapy Market Set to Soar: Breakthrough - openPR.com

Jun 19, 2025
pulisher
Jun 18, 2025

From Now to 2032: Unpacking the Genome Editing Market's - openPR.com

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga

Jun 18, 2025
pulisher
Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - AOL.com

Jun 17, 2025
pulisher
Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool

Jun 17, 2025
pulisher
Jun 17, 2025

Analysts Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat

Jun 17, 2025
pulisher
Jun 14, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Position Trimmed by Bank of America Corp DE - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Analysts Offer Predictions for Editas Medicine FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Editas Medicine (EDIT) Unveils Promising Gene Editing Data for B - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Kalkine: Editas Medicine’s In Vivo Gene Editing Progress Unveiled at EHA 2025 with tLNP Approach - Kalkine Media

Jun 12, 2025
pulisher
Jun 12, 2025

Breakthrough: New Gene Editing Therapy Achieves 58% Success Rate for Sickle Cell Disease Treatment - Stock Titan

Jun 12, 2025
pulisher
Jun 12, 2025

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hema - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Editas Medicine Reports 58% HBG1/2 Promoter Editing in Non-Human Primates Using High Efficiency tLNP Delivery Method - Nasdaq

Jun 12, 2025
pulisher
Jun 12, 2025

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - The Manila Times

Jun 12, 2025
pulisher
Jun 11, 2025

Why Is Editas (EDIT) Up 40% Since Last Earnings Report? - Yahoo Finance

Jun 11, 2025

Editas Medicine Inc Azioni (EDIT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Capitalizzazione:     |  Volume (24 ore):